Sun BioPharma, Inc. announced that David B. Kaysen, has been appointed President and Chief Executive Officer as well as a member of the company's Board of directors effective immediately. Mr. Kaysen joins the company as its lead development candidate, SBP-101, is expected to begin a Phase 1 clinical trial for the treatment of pancreatic cancer by the end of 2015. Prior to joining the company, Mr. Kaysen was an advisor and senior executive for several domestic and European growth-oriented privately-held healthcare companies.

He currently serves on the Board of Directors of four privately held companies, three of which are in the health care space.